Trial Profile
A Randomized Prospective Open Label Study of Switching to Raltegravir Based ART Compared to Maintaining Ritonavir Boosted PI-based ART on Liver Fibrosis Progression in HIV-HCV Coinfected Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Atazanavir; Darunavir; Lopinavir/ritonavir; Ritonavir
- Indications HIV infections
- Focus Adverse reactions
- 21 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 14 Jan 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 14 Jan 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.